Schistosomicidal, antifibrotic and antioxidant effects of Cucurbita pepo L. seed oil and praziquantel combined treatment for Schistosoma mansoni infection in a mouse model

• Published in: Journal of helminthology 2019-05, Vol.93 (3), p.286-294
• Main Authors: Beshay, E.V.N., Rady, A.A., Afifi, A.F., Mohamed, A.H.
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animals; Anthelmintics - administration & dosage; Anthelmintics - isolation & purification; Anthelmintics - pharmacology; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - isolation & purification; Anti-Inflammatory Agents - pharmacology; Antioxidants; Antioxidants - administration & dosage; Antioxidants - isolation & purification; Antioxidants - pharmacology; Antiparasitic agents; CD34 antigen; Collagen; Combined treatment; Cucurbita - chemistry; Cucurbita pepo; Disease Models, Animal; Drug dosages; Drug Therapy, Combination; Eggs; Enzymes; Ethics; Fatty acids; Fibrosis; Granuloma; Granulomas; Histopathology; Hypoxia; Infections; Laboratory animals; Liver; Malondialdehyde; Mice; Mollusks; Morphology; Oil; Oxidative stress; Parasites; Plant Oils - administration & dosage; Plant Oils - isolation & purification; Plant Oils - pharmacology; Praziquantel; Praziquantel - administration & dosage; Research Paper; Rodents; Scanning electron microscopy; Schistosoma mansoni; Schistosoma mansoni - drug effects; Schistosomiasis; Schistosomiasis mansoni - drug therapy; Seeds; Seeds - chemistry; Serum; Superoxide dismutase; Tissue; Treatment Outcome; Tropical diseases; Ultrastructure; Worms
• ISSN: 0022-149X; 1475-2697
• DOI: 10.1017/S0022149X18000317

Despite the seriousness of schistosomiasis, its treatment depends only on praziquantel (PZQ), which has begun to lose its efficacy against the emergent Schistosoma mansoni-resistant strains. Therefore, the discovery of a novel schistosomicidal drug is an urgent priority. This study was designed to evaluate treatment with Cucurbita pepo L. (pumpkin) seed oil (PSO) alone and combined with PZQ against S. mansoni in experimentally infected mice. The study involved five groups: GI was the normal control; GII was the infected control; GIII was treated with an oral dose of PZQ of 500 mg/kg/day for two successive days, starting in the sixth week post infection; GIV was treated with an oral dose of PSO of 50 mg/kg/day for four weeks, starting in the fourth week post infection; and GV was treated with combined PSO–PZQ. Worm burden, tissue egg load and oogram pattern were estimated, and the ultrastructure alterations were examined. Histopathological examination of granuloma diameters, collagen deposition (Picro Sirius red stain), and angiogenesis (immunohistochemical expression of CD34+) was conducted and serum liver enzymes were measured to assess the liver condition. Moreover, the oxidative stress was evaluated by determining the amounts of malondialdehyde and superoxide dismutase in liver homogenates. The results revealed significant changes in all the assessed parameters with PSO administration. However, PZQ was significantly more effective as an antiparasitic agent, whereas PSO was better in terms of fibrosis and oxidative stress. The most significant results were obtained in group V, which may be attributed to a synergy between PZQ and PSO, with antiparasitic, antioxidant and antifibrotic properties.